Do analysts recommend TIL or BLRX?

Instil Bio presently has a consensus price target of $66.00, suggesting a potential upside of 710.81%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TIL or BLRX more profitable?

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% BioLineRx -563.70% -37.73% -19.42%

Do analysts recommend BLRX or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 922.01%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mereo BioPharma Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Do analysts prefer ACTU or BLRX?

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 806.74%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ACTU or BLRX?

In the previous week, BioLineRx had 6 more articles in the media than Actuate Therapeutics. MarketBeat recorded 8 mentions for BioLineRx and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.29 beat BioLineRx's score of 0.75 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INKT or BLRX?

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 174.51%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe MiNK Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer INKT or BLRX?

In the previous week, BioLineRx had 7 more articles in the media than MiNK Therapeutics. MarketBeat recorded 8 mentions for BioLineRx and 1 mentions for MiNK Therapeutics. BioLineRx's average media sentiment score of 0.75 beat MiNK Therapeutics' score of 0.62 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BLRX or GOSS?

Gossamer Bio has a consensus target price of $5.00, indicating a potential upside of 2,712.15%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is BLRX or GOSS more profitable?

Gossamer Bio has a net margin of -324.82% compared to BioLineRx's net margin of -563.70%. Gossamer Bio's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Gossamer Bio -324.82% N/A -96.10%

Does the media favor BLRX or GOSS?

In the previous week, Gossamer Bio had 12 more articles in the media than BioLineRx. MarketBeat recorded 20 mentions for Gossamer Bio and 8 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.75 beat Gossamer Bio's score of 0.15 indicating that BioLineRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 2 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioLineRx (BLRX) Competitors

$3.36 +0.08 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 0.00 (-0.15%)

As of 04:10 PM Eastern

Compare

BLRX vs. TIL, MREO, ACTU, INKT, and GOSS

Should you buy BioLineRx stock or one of its competitors? MarketBeat compares BioLineRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLineRx include Instil Bio (TIL), Mereo BioPharma Group (MREO), Actuate Therapeutics (ACTU), MiNK Therapeutics (INKT), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.

How does BioLineRx compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
BioLineRx	-563.70%	-37.73%	-19.42%

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLineRx has higher revenue and earnings than Instil Bio. BioLineRx is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
BioLineRx	$1.18M	12.44	-$1.17M	-$1.92	N/A

Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

In the previous week, BioLineRx had 8 more articles in the media than Instil Bio. MarketBeat recorded 8 mentions for BioLineRx and 0 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat BioLineRx's score of 0.75 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
BioLineRx	Positive

Instil Bio presently has a consensus price target of $66.00, suggesting a potential upside of 710.81%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioLineRx beats Instil Bio on 8 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Mereo BioPharma Group?

BioLineRx (NASDAQ:BLRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 922.01%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, BioLineRx had 8 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for BioLineRx and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat BioLineRx's score of 0.75 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

BioLineRx has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

BioLineRx has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.44	-$1.17M	-$1.92	N/A
Mereo BioPharma Group	$500K	101.52	-$41.88M	-$0.05	N/A

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Mereo BioPharma Group beats BioLineRx on 9 of the 16 factors compared between the two stocks.

How does BioLineRx compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Actuate Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
BioLineRx	-563.70%	-37.73%	-19.42%

BioLineRx has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
BioLineRx	$1.18M	12.44	-$1.17M	-$1.92	N/A

Actuate Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 806.74%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.6% of BioLineRx shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioLineRx had 6 more articles in the media than Actuate Therapeutics. MarketBeat recorded 8 mentions for BioLineRx and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.29 beat BioLineRx's score of 0.75 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLineRx beats Actuate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BioLineRx compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

BioLineRx has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
BioLineRx	$1.18M	12.44	-$1.17M	-$1.92	N/A

In the previous week, BioLineRx had 7 more articles in the media than MiNK Therapeutics. MarketBeat recorded 8 mentions for BioLineRx and 1 mentions for MiNK Therapeutics. BioLineRx's average media sentiment score of 0.75 beat MiNK Therapeutics' score of 0.62 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 174.51%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe MiNK Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. MiNK Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
BioLineRx	-563.70%	-37.73%	-19.42%

Summary

BioLineRx beats MiNK Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Gossamer Bio?

BioLineRx (NASDAQ:BLRX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, Gossamer Bio had 12 more articles in the media than BioLineRx. MarketBeat recorded 20 mentions for Gossamer Bio and 8 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.75 beat Gossamer Bio's score of 0.15 indicating that BioLineRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	2 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a consensus target price of $5.00, indicating a potential upside of 2,712.15%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioLineRx has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Gossamer Bio has a net margin of -324.82% compared to BioLineRx's net margin of -563.70%. Gossamer Bio's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Gossamer Bio	-324.82%	N/A	-96.10%

BioLineRx has higher earnings, but lower revenue than Gossamer Bio. BioLineRx is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.44	-$1.17M	-$1.92	N/A
Gossamer Bio	$48.47M	0.86	-$170.37M	-$0.79	N/A

Summary

Gossamer Bio beats BioLineRx on 12 of the 16 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.68M	$2.97B	$6.44B	$12.47B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-1.75	18.12	23.87	24.40
Price / Sales	12.44	303.58	521.86	117.01
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	0.63	3.94	9.99	6.73
Net Income	-$1.17M	$75.85M	$3.56B	$337.03M
7 Day Performance	-6.41%	-1.12%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-27.90%	23.05%	28.77%	34.24%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	1.2439 of 5 stars	$3.36 +2.4%	N/A	-22.3%	$14.68M	$1.18M	N/A	40	Analyst Revision
TIL Instil Bio	2.5351 of 5 stars	$8.15 -0.4%	$66.00 +709.8%	-72.5%	$55.26M	N/A	N/A	410
MREO Mereo BioPharma Group	3.5805 of 5 stars	$0.34 +21.4%	$3.25 +862.1%	-87.4%	$53.92M	$500K	N/A	40	Positive News High Trading Volume
ACTU Actuate Therapeutics	3.1065 of 5 stars	$2.24 -5.9%	$17.50 +681.3%	-81.3%	$53.60M	N/A	N/A	10	Gap Up
INKT MiNK Therapeutics	2.6005 of 5 stars	$10.54 -3.0%	$35.00 +232.1%	+79.0%	$52.49M	N/A	N/A	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. TIL, MREO, ACTU, INKT, and GOSS

How does BioLineRx compare to Instil Bio?

Summary

How does BioLineRx compare to Mereo BioPharma Group?

Summary

How does BioLineRx compare to Actuate Therapeutics?

Summary

How does BioLineRx compare to MiNK Therapeutics?

Summary

How does BioLineRx compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. TIL, MREO, ACTU, INKT, and GOSS

How does BioLineRx compare to Instil Bio?

Is TIL or BLRX more profitable?

Do insiders and institutionals have more ownership in TIL or BLRX?

Which has better earnings and valuation, TIL or BLRX?

Which has more risk and volatility, TIL or BLRX?

Does the media prefer TIL or BLRX?

Do analysts recommend TIL or BLRX?

Summary

How does BioLineRx compare to Mereo BioPharma Group?

Do analysts recommend BLRX or MREO?

Does the media favor BLRX or MREO?

Is BLRX or MREO more profitable?

Which has more volatility and risk, BLRX or MREO?

Which has higher valuation and earnings, BLRX or MREO?

Do institutionals & insiders have more ownership in BLRX or MREO?

Summary

How does BioLineRx compare to Actuate Therapeutics?

Is ACTU or BLRX more profitable?

Which has higher valuation and earnings, ACTU or BLRX?

Which has more volatility & risk, ACTU or BLRX?

Do analysts prefer ACTU or BLRX?

Do institutionals and insiders have more ownership in ACTU or BLRX?

Does the media refer more to ACTU or BLRX?

Summary

How does BioLineRx compare to MiNK Therapeutics?

Which has stronger valuation and earnings, INKT or BLRX?

Does the media prefer INKT or BLRX?

Which has more risk & volatility, INKT or BLRX?

Do analysts rate INKT or BLRX?

Do institutionals & insiders have more ownership in INKT or BLRX?

Is INKT or BLRX more profitable?

Summary

How does BioLineRx compare to Gossamer Bio?

Does the media favor BLRX or GOSS?

Do analysts recommend BLRX or GOSS?

Do insiders & institutionals believe in BLRX or GOSS?

Which has more volatility & risk, BLRX or GOSS?

Is BLRX or GOSS more profitable?

Which has stronger valuation & earnings, BLRX or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools